These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11418309)

  • 41. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC.
    van Leeuwen EB; Cloosen S; Senden-Gijsbers BL; Germeraad WT; Bos GM
    Cytotherapy; 2006; 8(1):36-46. PubMed ID: 16627343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
    Yamanaka R; Xanthopoulos KG
    DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
    Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
    Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
    Becker JT; Olson BM; Johnson LE; Davies JG; Dunphy EJ; McNeel DG
    J Immunother; 2010; 33(6):639-47. PubMed ID: 20551832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
    He SB; Sun K; Wang L; Li DC; Zhang YY
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
    Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
    Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
    Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.
    Qiu SJ; Lu L; Qiao C; Wang L; Wang Z; Xiao X; Qian S; Fung JJ; Ye SL; Bonham CA
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):429-38. PubMed ID: 15818505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
    Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J
    J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
    Xiang R; Primus FJ; Ruehlmann JM; Niethammer AG; Silletti S; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    J Immunol; 2001 Oct; 167(8):4560-5. PubMed ID: 11591784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
    Balint JP; Gabitzsch ES; Rice A; Latchman Y; Xu Y; Messerschmidt GL; Chaudhry A; Morse MA; Jones FR
    Cancer Immunol Immunother; 2015 Aug; 64(8):977-87. PubMed ID: 25956394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.
    Gastl G; Finstad CL; Guarini A; Bosl G; Gilboa E; Bander NH; Gansbacher B
    Cancer Res; 1992 Nov; 52(22):6229-36. PubMed ID: 1423266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
    Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.